Abciximab
Trade names
REOPRO
Actions
- Glycoprotein IIb/IIIa inhibitor.
Route of Administration
Intravenous
Bioavailability
100%
Plasma protein binding
Not available
Time to peak plasma concentration
Dose dependent
Time to plasma steady state
Not available
Half-life
10–15 min
Elimination
Not available
Duration of action
12 h
Reversible platelet inhibition
No
Recommended dose
Bolus dose of 0.25 mg/kg followed by a continuous infusion of 0.125 μg/kg/min (max 10 μg/min) for 12 hours.
Indicated as adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.
Renal impairment
Careful consideration of risk/benefit is advised in patients with severe renal impairment (creatinine clearance <30 ml/min).
Discontinuation before invasive procedures
48 h